IVAX Diagnostics Exhibits at FIME

IVAX Diagnostics, Inc. (NYSE Amex:IVD), a fully integrated in vitro diagnostics company, announced that its wholly-owned subsidiary – Diamedix Corporation – is participating as an exhibitor in the 2011 FIME International Medical Expo in Miami Beach, Florida. The annual meeting, which takes place August 10-12, 2011, is the largest international medical expo in the United States occupying 500,000 square feet of the Miami Beach Convention Center with 1,300 exhibitors and 41,216 registered attendees.

Kevin Clark, President, Chief Executive Officer and Chief Operating Officer of IVAX Diagnostics, said, “We are pleased to be participating as an exhibitor at FIME, which is the largest international Medical Expo in the US. We are showcasing our complete product line, including our Mago® 4S automated ELISA and IFA instrumentation system that received 510(k) clearance from the U.S. Food and Drug Administration earlier this year, at booth #483. IVAX Diagnostics also plans to launch its sales of ERBA Diagnostics Mannheim GmbH’s full line of products in the North and South American markets. ERBA Diagnostics Mannheim, an in vitro diagnostics company headquartered in Germany, is the owner, directly or indirectly, of approximately 77.8% of the issued and outstanding shares of our common stock.”

About IVAX Diagnostics, Inc.

IVAX Diagnostics, Inc. (www.ivaxdiagnostics.com), headquartered in Miami, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, through its three subsidiaries: Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe), and ImmunoVision, Inc. (U.S.).

Safe Harbor Statement

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect the business and prospects of IVAX Diagnostics, Inc., including, without limitation: the risks and uncertainties associated with IVAX Diagnostics’ plans to launch its sales of ERBA Diagnostics Mannheim’s full line of products in the North and South American markets, including, without limitation, that IVAX Diagnostics’ launch of such sales may not occur when anticipated, that such sales by IVAX Diagnostics may not achieve anticipated levels, that such sales may not expand IVAX Diagnostics’ market reach and penetration, that IVAX Diagnostics may not be able to achieve its goal of expanding its presence and market reach in markets outside of the U.S., such as the North and South American markets, and that such sales may not provide IVAX Diagnostics with, or otherwise allow IVAX Diagnostics to achieve, its intended results, whether business, financial or otherwise; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. Investors should consider the economic, competitive, governmental, technological and other risks and uncertainties discussed in IVAX Diagnostics’ filings with the Securities and Exchange Commission, including, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in such filings.

Ivax Diagnostics (AMEX:IVD)
Historical Stock Chart
From May 2024 to Jun 2024